ORM1 (orosomucoid 1) encodes an acute-phase protein that constitutes 1-3% of plasma proteins and is primarily synthesized in the liver 1. As a transport protein, ORM1 functions in drug binding and influences drug distribution and availability in the body, while also modulating immune system activity during acute-phase reactions 1. The protein demonstrates tissue-protective effects, particularly in cartilage homeostasis where it binds to vimentin and inhibits the MAPK pathway, thereby suppressing matrix metalloproteinase-mediated cartilage degradation 2. ORM1 also regulates plasma cell-free DNA levels, which serve as surrogate markers for neutrophil extracellular traps involved in immunothrombosis 3. The gene exhibits genetic polymorphism with three common alleles (F1, F2, S) resulting from specific nucleotide transitions 4. In disease contexts, ORM1 shows decreased expression in liver diseases and temporomandibular joint osteoarthritis 12, while increased expression correlates with podocyte damage in lupus nephritis through AMPK/mTOR signaling modulation 5. These findings suggest ORM1 functions as both a protective factor in tissue homeostasis and a potential therapeutic target in inflammatory and degenerative diseases.